Mangoceuticals, Inc. Form 8-K Filing

Mangoceuticals, Inc. filed a Form 8-K on March 16, 2026, to report an option repricing for its CEO, Jacob Cohen. The repricing reduced the exercise price of outstanding stock options to $0.45 per share, aligning with the closing stock price on the effective date. This action was approved by the Board of Directors upon recommendation from the Compensation and Audit Committees, with Mr. Cohen recusing himself from the vote. Additionally, on March 17, 2026, the company issued a press release announcing a lawsuit against Clarity Ventures, Inc., a former technology consulting firm, seeking over $73 million in damages for failure to deliver a functional ERP and eCommerce platform. Clarity Ventures has denied the allegations and filed counterclaims for unpaid invoices, which Mangoceuticals disputes.